What Ventas (VTR) Investors Need to Know

Join us for a quick overview of Ventas, a Specialty Real Estate Investment Trust company whose shares moved 0.4% today. Here are some facts about the stock that should help you see the bigger picture:

  • Ventas has moved -9.0% over the last year, and the S&P 500 logged a change of 11.0%

  • VTR has an average analyst rating of buy and is -16.85% away from its mean target price of $52.0 per share

  • Its trailing earnings per share (EPS) is $0.22

  • Ventas has a trailing 12 month Price to Earnings (P/E) ratio of 196.5 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $0.2 and its forward P/E ratio is 216.2

  • The company has a Price to Book (P/B) ratio of 1.74 in contrast to the S&P 500's average ratio of 2.95

  • Ventas is part of the Real Estate sector, which has an average P/E ratio of 24.81 and an average P/B of 2.24

  • The company has a free cash flow of $912.35 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • Ventas Inc., an S&P 500 company, operates at the intersection of two large and dynamic industries – healthcare and real estate. Fueled by powerful demographic demand from growth in the aging population, Ventas owns or has investments in a highly diversified portfolio of approximately 1,400 properties in the United States, Canada, and the United Kingdom. Ventas uses the power of its capital to unlock the value of senior housing communities, outpatient medical buildings, research centers, hospitals and other healthcare facilities. A globally-recognized real estate investment trust, Ventas follows a successful long-term strategy, proven over more than 20 years, built on diversification of property types, capital sources and industry leading partners, financial strength and flexibility, consistent and reliable growth and industry leading ESG achievements, managed by a collaborative and experienced team dedicated to its stakeholders.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.